Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 21;4(1):81–95. doi: 10.1038/s43018-022-00502-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, Infection neutralization IC₅₀ values for the Delta VoC. b, Infection neutralization IC₅₀ values for the Omicron (BA.1) VoC. Neutralization IC₅₀ values in serum are depicted for different SARS-CoV-2 variants as box plots with median, bounds between upper and lower quartiles and whiskers between the 10th and 90th percentiles. Differences between time points were tested for their statistical significance using the Kruskal–Wallis test with Dunn’s multiple-testing correction. Brackets show statistically significant differences, and precise numerical P values are indicated. Absence of brackets or P values indicates absence of statistical significance. Sera from the following subgroups of individuals were analyzed at visit 2 (blue), visit 3 (yellow) and visit 4 (red); untreated LY (Delta VoC: visit 2/visit 3/visit 4: N = 8/6/8, respectively; Omicron (BA.1) VoC: visit 2/visit 3/visit 4: N = 8/6/8, respectively); individuals with LY treated with Rx 12–60 months before receiving the first vaccination (Rx 12–60; Delta: visit 2/visit 3/visit 4: N = 9/7/6, respectively; Omicron (BA.1): visit 2/visit 3/visit 4: N = 9/7/6, respectively); individuals with LY treated with Rx in the last 12 months before the first vaccination (Rx < 12; Delta: visit 2/visit 3/visit 4: N = 14/9/10, respectively; Omicron (BA.1): visit 2/visit 3/visit 4: N = 14/9/9, respectively); untreated MM (Delta: visit 2/visit 3/visit 4: N = 9/9/8, respectively; Omicron (BA.1): visit 2/visit 3/visit 4: N = 9/8/8, respectively); treated MM (Delta: visit 2/visit 3/visit 4: N = 12/8/9, respectively; Omicron (BA.1): visit 2/visit 3/visit 4: N = 12/8/9, respectively).

Source data